- Home
- LYFT vs PCVX Comparison
LYFT vs PCVX Comparison
Compare LYFT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | PCVX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LYFT | PCVX |
|---|---|---|
| Price | $13.31 | $60.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 7 |
| Target Price | $20.17 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 17.7M | 1.4M |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | N/A |
| EPS | ★ 6.81 | N/A |
| Revenue | ★ $6,316,261,000.00 | N/A |
| Revenue This Year | $18.09 | N/A |
| Revenue Next Year | $12.16 | N/A |
| P/E Ratio | $2.02 | ★ N/A |
| Revenue Growth | ★ 9.16 | N/A |
| 52 Week Low | $9.66 | $28.09 |
| 52 Week High | $25.54 | $76.61 |
Technical Indicators
Market Signals| Indicator | LYFT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 59.15 |
| Support Level | $13.09 | $42.30 |
| Resistance Level | $15.58 | N/A |
| Average True Range (ATR) | 0.62 | 3.27 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 16.30 | 62.30 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.